Premium
Pharmacological corrections of the mutant hERG channels by posaconazole
Author(s) -
Luo Chaodi,
Zheng Xinglong,
Li Jing,
Zhang Yongjian,
Shi Tao,
Yan Yang,
Han Dan
Publication year - 2021
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.13475
Subject(s) - herg , hek 293 cells , chemistry , mutant , posaconazole , pharmacology , patch clamp , potassium channel , microbiology and biotechnology , biophysics , biochemistry , biology , receptor , gene , antifungal , amphotericin b
Properties of mutant human ether‐à‐go‐go‐related gene (hERG) channels can be modified by some antibiotics. However, the pharmacological effects of posaconazole on cardiomyocyte hERG channels remain unclear. Whole‐cell patch clamping, western blotting and laser confocal scanning microscopy were used to evaluate the effects of posaconazole on wild‐type (WT)‐, A561V‐ and L539 fs/47‐hERG channels expressed in human embryonic kidney (HEK) 293 cells. In electrophysiological experiments, HEK 293 cells were transiently co‐transfected with equal amounts of WT‐hERG, WT+A561 V‐hERG and WT+L539 fs/47‐hERG plasmids to mimic a heterozygous genotype. Posaconazole (30 μM) increased tail currents in cells expressing WT‐hERG, WT+A561 V‐hERG and WT+L539 fs/47‐hERG by 82.65%, 147.72% and 134.73%, respectively, compared to controls. Posaconazole increased hERG protein expression in cells expressing WT‐hERG, WT+A561 V‐hERG and WT+L539 fs/47‐hERG compared to controls condition as well as their trafficking to the cell membrane. To our knowledge, this is the first study to show that antifungal agent posaconazole rescues the mutant A561 V‐hERG and L539 fs/47‐hERG channels by altering the gating kinetics, enhancing the expression and trafficking of hERG channels. The results demonstrate that posaconazole could be a promising candidate for the prevention and treatment of long QT syndrome and other arrhythmia‐related diseases.